By Gina Shaw
Asparaginase-based regimens have been a cornerstone in the treatment of pediatric acute lymphoblastic leukemia (ALL). But these treatments are increasingly being used to treat adult ALL as well, in the wake of clinical trials that demonstrated a significant survival benefit with pediatric-inspired regimens (J Clin Oncol 2009;27[6]:911-918; Cancer 2014;120[23]:3660-3668). In both adults and children, however, asparaginase is challenging to manage, due to hypersensivity reactions in
JANUARY 14, 2022